With Takhzyro Approval, Shire Could Reclaim HAE Prophylaxis Market From CSL Behring

 
• By Joseph Haas

Offering better efficacy than Shire’s existing HAE therapies and dosing convenience compared to CSL Behring’s prophylactic Haegarda, the specialty pharma may take back market share lost to its competitor and consolidate its leadership in the space.

Red Approved Stamp with Wooden handle Rubber Stamper Isolated on White Background.

More from New Products

More from Scrip